Sagimet Biosciences Valuation
Is 0O2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0O2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 0O2's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 0O2's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0O2?
Key metric: As 0O2 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 0O2's PB Ratio? | |
|---|---|
| PB Ratio | 0.9x |
| Book | US$170.68m |
| Market Cap | US$159.37m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 0O2's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.9x | ||
2INV 2invest | 1.1x | n/a | €67.3m |
HPHA Heidelberg Pharma | 3x | -33.0% | €105.8m |
FYB Formycon | 1.6x | 30.6% | €905.8m |
BIO3 Biotest | 1.9x | 29.3% | €1.3b |
0O2 Sagimet Biosciences | 0.9x | -32.7% | €159.4m |
Price-To-Book vs Peers: 0O2 is good value based on its Price-To-Book Ratio (0.9x) compared to the peer average (1.9x).
Price to Book Ratio vs Industry
How does 0O2's PB Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Book vs Industry: 0O2 is good value based on its Price-To-Book Ratio (0.9x) compared to the European Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is 0O2's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.9x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 0O2's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €4.78 | €27.54 +476.2% | 62.0% | €63.32 | €5.67 | n/a | 7 |
| Dec ’25 | €5.20 | €27.47 +428.3% | 67.0% | €63.10 | €5.65 | n/a | 6 |
| Nov ’25 | €4.96 | €29.45 +493.8% | 60.3% | €60.53 | €5.42 | n/a | 5 |
| Oct ’25 | €2.46 | €29.45 +1,097.2% | 60.3% | €60.53 | €5.42 | n/a | 5 |
| Sep ’25 | €2.76 | €29.59 +972.3% | 60.3% | €60.82 | €5.45 | n/a | 5 |
| Aug ’25 | €3.06 | €33.42 +992.1% | 57.5% | €62.54 | €5.60 | n/a | 5 |
| Jul ’25 | €3.10 | €33.42 +978.0% | 57.5% | €62.54 | €5.60 | n/a | 5 |
| Jun ’25 | €5.00 | €36.09 +621.8% | 41.7% | €61.69 | €21.18 | n/a | 5 |
| May ’25 | €3.88 | €38.80 +899.9% | 40.2% | €61.89 | €24.02 | n/a | 4 |
| Apr ’25 | €5.25 | €38.80 +639.0% | 40.2% | €61.89 | €24.02 | n/a | 4 |
| Mar ’25 | €5.60 | €46.49 +730.2% | 25.1% | €62.30 | €34.40 | n/a | 3 |
| Feb ’25 | €8.75 | €46.40 +430.3% | 24.8% | €61.77 | €34.11 | n/a | 3 |
| Jan ’25 | €5.20 | €39.52 +660.0% | 40.3% | €62.06 | €27.79 | n/a | 3 |
| Dec ’24 | €3.46 | €39.87 +1,052.2% | 40.3% | €62.60 | €28.03 | €5.20 | 3 |
| Nov ’24 | n/a | €41.03 0% | 38.7% | €63.44 | €28.40 | €4.96 | 3 |
| Oct ’24 | n/a | €41.03 0% | 38.7% | €63.44 | €28.40 | €2.46 | 3 |
| Sep ’24 | n/a | €39.77 0% | 38.7% | €61.49 | €27.53 | €2.76 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sagimet Biosciences Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrea Tan | Goldman Sachs |
| Andrea Newkirk | Goldman Sachs |
| Antonio Arce | H.C. Wainwright & Co. |